Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA AG    MRK   DE0006599905

MERCK KGAA AG

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Gets FDA Breakthrough-Therapy Designation for Tepotinib

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/11/2019 | 06:35am EDT

By Colin Kellaher

Merck KGaA (MRK.XE) Wednesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to its tepotinib investigational therapy in a form of lung cancer.

The Darmstadt, Germany, science and technology company said the designation covers tepotinib in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.

Lung cancer is one of the most common types of cancer worldwide. Merck said alterations of the MET signaling pathway are found in 3% to 5% of non-small cell lung cancer cases and correlate with aggressive tumor behavior and poor clinical prognosis.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA AG
07:15aMerck Gets FDA Priority Review for Investigational Ebola Zaire Virus Vaccine
DJ
09/12MERCK KGAA : Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation ..
AQ
09/11MERCK : Gets FDA Breakthrough-Therapy Designation for Tepotinib
DJ
09/11MERCK : Darmstadt, Germany, on Track to Deliver Sustainable Profitable Growth - ..
PU
09/11MERCK : Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for I..
PU
09/11MERCK : Darmstadt, Germany, on Track to Deliver Sustainable Profitable Growth
PU
09/11MERCK : Backs 2019 View; Sees Profitable Growth Over Next Years
DJ
09/10Merck Down Nearly 5%, on Pace for Largest Percent Decrease Since October 2017..
DJ
09/10MERCK : Darmstadt, Germany Initiates Pivotal Phase III Program for Investigation..
PU
09/09MERCK : Updated Results for Investigational Therapy Tepotinib Presented at WCLC ..
PU
More news
Financials (EUR)
Sales 2019 15 600 M
EBIT 2019 2 255 M
Net income 2019 1 481 M
Debt 2019 5 764 M
Yield 2019 1,32%
P/E ratio 2019 29,0x
P/E ratio 2020 23,0x
EV / Sales2019 3,12x
EV / Sales2020 2,87x
Capitalization 42 878 M
Chart MERCK KGAA AG
Duration : Period :
Merck KGaA AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 103,05  €
Last Close Price 99,34  €
Spread / Highest target 22,8%
Spread / Average Target 3,73%
Spread / Lowest Target -17,5%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA AG9.60%47 575
WUXI APPTEC CO LTD51.43%18 573
KYOWA KIRIN CO LTD3.60%10 212
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD15.45%8 454
JAZZ PHARMACEUTICALS PLC8.11%7 588
BETTA PHARMACEUTICALS CO LTD--.--%2 664